Sangamo Biosciences shot up 20% today, but this may still be one to watch at a distance.
Biogen, Eisai join up in Alzheimer’s drug pact.
Sangamo shares soared after it released intriguing clinical data in its attempt to treat HIV. Should shareholders be excited or cautious regarding Sangamo's move higher?
Isis may not be profitable yet, but its RNA antisense discovery platform continues to churn out viable drug candidates.
Xoma, Biogen, Agenus, and GSK could all loom large in health care headlines this morning.See More Articles...